Pretargeted radioimmunotherapy for hematologic and other malignancies.

Abstract

Radioimmunotherapy (RIT) has emerged as one of the most promising treatment options, particularly for hematologic malignancies. However, this approach has generally been limited by a suboptimal therapeutic index (target-to-nontarget ratio) and an inability to deliver sufficient radiation doses to tumors selectively. Pretargeted RIT (PRIT) circumvents these limitations by separating the targeting vehicle from the subsequently administered therapeutic radioisotope, which binds to the tumor-localized antibody or is quickly excreted if unbound. A growing number of preclinical proof-of-principle studies demonstrate that PRIT is feasible and safe and provides improved directed radionuclide delivery to malignant cells compared with conventional RIT while sparing normal cells from nonspecific radiotoxicity. Early phase clinical studies corroborate these preclinical findings and suggest better efficacy and lesser toxicities in patients with hematologic and other malignancies. With continued research, PRIT-based treatment strategies promise to become cornerstones to improved outcomes for cancer patients despite their complexities.

• Authors: Roland B Walter, Oliver W Press, John M Pagel
• Journal: Cancer biotherapy & radiopharmaceuticals (Cancer Biother Radiopharm) Vol. 25 Issue 2 Pg. 125-42 (Apr 2010) ISSN: 1557-8852 [Electronic] United States
• PMID: 20423225 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Radiopharmaceuticals

Topics

• Animals
• Antineoplastic Agents (therapeutic use)
• Clinical Trials as Topic
• Hematologic Neoplasms (immunology, metabolism, radiotherapy)
• Humans
• Radioimmunotherapy
• Radiopharmaceuticals (therapeutic use)
• Treatment Outcome
• Xenograft Model Antitumor Assays